International Conference on Harmonisation; Draft Guidance on Q4B Regulatory Acceptance of Analytical Procedures and/or Acceptance Criteria; Annex on Residue on Ignition/Sulphated Ash General Chapter; Availability, 45058-45059 [E6-12806]
Download as PDF
45058
Federal Register / Vol. 71, No. 152 / Tuesday, August 8, 2006 / Notices
FOR FURTHER INFORMATION CONTACT:
Michael B. Fauntleroy, CBER (HFM–25),
Food and Drug Administration, 11400
Rockville Pike, RKWL rm. 4119,
Rockville, MD 20857, 301–827–5132, email: michael.fauntleroy@fda.hhs.gov or
William H. Taylor, Office of the
Commissioner (HFA–83), Food and
Drug Administration, 5600 Fishers
Lane, rm. 16B–45, Rockville, MD 20857,
301–255–6734, e-mail:
william.taylor@fda.hhs.gov.
FDA
receives a variety of electronic
submissions under 21 CFR 11.2(b),
including biological license applications
(BLAs), new drug applications (NDAs),
drug master files (DMFs), investigational
new drug applications (INDs), and
investigational device exemptions
(IDEs), as well as their associated
correspondence and other types of
regulatory submissions. The FDA ESG
supports the receipt and processing of
electronic submissions through the use
of a single point of entry.
The increasing number of electronic
submissions highlights a critical need to
automate and standardize the receipt of
these submissions and their delivery to
the appropriate centers. The FDA ESG
automates the receipt, acknowledgment
(to the applicant/sponsor), routing, and
notification (to a receiving center) of
electronic submissions via the Internet
and meets the standards for the
electronic exchange of information
adopted by the American National
Standards Institute (ANSI) and the
National Institute of Standards and
Technology (NIST).
The FDA ESG offers two secure
communication options for applicants
that have established gateway systems.
One utilizes simple mail transfer
protocol (SMTP) with secure multipurpose internet mail extensions (S/
MIME) to provide secure e-mail
communication and the other supports
faster information exchange and utilizes
hypertext transfer protocol secure
(HTTPS) to provide real-time Internet
communication. The FDA ESG also
offers a secure WebTrader submission
option for applicants who do not have
gateway systems. The WebTrader is a
no-cost applet which can be
downloaded from FDA and requires
only a standard security certificate to
provide the applicants with a secure
Internet connection to FDA. The
WebTrader addresses the need to
expand participation in electronic
submissions without costly
expenditures for infrastructure upgrades
and gateway systems.
Use of the FDA ESG is voluntary.
Electronic format submissions may be
jlentini on PROD1PC65 with NOTICES
SUPPLEMENTARY INFORMATION:
VerDate Aug<31>2005
20:06 Aug 07, 2006
Jkt 208001
made through the gateway or may
continue to be made on physical media.
Information on the FDA ESG is available
on the following Web site: https://
www.fda.gov/esg/. Except where FDA
has promulgated regulations requiring
submission in electronic format,
applicants/sponsors may also continue
to make regulatory submissions on
paper.
If you wish to use the FDA ESG, you
should send an e-mail to
esgprep@fda.gov to begin the
registration process. Include your name,
phone number, and the name of the
company you represent. Please state
whether you are using the WebTrader,
SMTP, or HTTPS for submissions.
Dated: July 31, 2006.
Jeffrey Shuren,
Assistant Commissioner for Policy.
[FR Doc. E6–12808 Filed 8–7–06; 8:45 am]
BILLING CODE 4160–01–S
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. 2006D–0296]
International Conference on
Harmonisation; Draft Guidance on Q4B
Regulatory Acceptance of Analytical
Procedures and/or Acceptance
Criteria; Annex on Residue on Ignition/
Sulphated Ash General Chapter;
Availability
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Notice.
SUMMARY: The Food and Drug
Administration (FDA) is announcing the
availability of a draft guidance entitled
‘‘Q4B Regulatory Acceptance of
Analytical Procedures and/or
Acceptance Criteria; Annex 1: Residue
on Ignition/Sulphated Ash General.’’
The draft guidance was prepared under
the auspices of the International
Conference on Harmonisation of
Technical Requirements for Registration
of Pharmaceuticals for Human Use
(ICH). The draft guidance provides the
outcome of the ICH Q4B evaluation of
the Residue on Ignition/Sulphated Ash
General Chapter harmonized text from
each of the three pharmacopoeias
(United States, European, and Japanese)
represented by the Pharmacopoeial
Discussion Group (PDG). The draft
guidance conveys acceptance of the
three pharmacopoeial methods by the
three ICH regulatory regions and
provides specific information regarding
the acceptance. The draft guidance is
PO 00000
Frm 00065
Fmt 4703
Sfmt 4703
intended to recognize the
interchangeability between the local
regional pharmacopoeias, thus avoiding
redundant testing and different
acceptance criteria in favor of a common
testing strategy in each regulatory
region. Elsewhere in this issue of the
Federal Register, FDA is announcing the
availability of a draft guidance entitled
‘‘Q4B Regulatory Acceptance of
Analytical Procedures and/or
Acceptance Criteria.’’
Submit written or electronic
comments on the draft guidance by
October 10, 2006.
DATES:
Submit written requests for
single copies of the draft guidance to the
Division of Drug Information (HFD–
240), Center for Drug Evaluation and
Research, Food and Drug
Administration, 5600 Fishers Lane,
Rockville, MD 20857; or the Office of
Communication, Training and
Manufacturers Assistance (HFM–40),
Center for Biologics Evaluation and
Research (CBER), Food and Drug
Administration, 1401 Rockville Pike,
Rockville, MD 20852–1448. The
guidance may also be obtained by mail
by calling CBER at 1–800–835–4709 or
301–827–1800. Send two self-addressed
adhesive labels to assist the office in
processing your requests. Submit
written comments on the draft guidance
to the Division of Dockets Management
(HFA–305), Food and Drug
Administration, 5630 Fishers Lane, rm.
1061, Rockville, MD 20852. Submit
electronic comments to https://
www.fda.gov/dockets/ecomments. See
the SUPPLEMENTARY INFORMATION section
for electronic access to the draft
guidance document.
ADDRESSES:
FOR FURTHER INFORMATION CONTACT:
Regarding the guidance: Robert H.
King, Sr., Center for Drug
Evaluation and Research (HFD–
003), Food and Drug
Administration, 10993 New
Hampshire Ave., Bldg. 21, rm. 3542,
Silver Spring, MD 20993–0002,
301–796–1242; or
Christopher Joneckis, Center for
Biologics Evaluation and Research
(HFM–20), Food and Drug
Administration, 1401 Rockville
Pike, Rockville, MD 20852, 301–
435–5681.
Regarding the ICH:Michelle Limoli,
Office of International Programs
(HFG–1), Food and Drug
Administration, 5600 Fishers
Lane,Rockville, MD 20857, 301–
827–4480.
SUPPLEMENTARY INFORMATION:
E:\FR\FM\08AUN1.SGM
08AUN1
Federal Register / Vol. 71, No. 152 / Tuesday, August 8, 2006 / Notices
jlentini on PROD1PC65 with NOTICES
I. Background
In recent years, many important
initiatives have been undertaken by
regulatory authorities and industry
associations to promote international
harmonization of regulatory
requirements. FDA has participated in
many meetings designed to enhance
harmonization and is committed to
seeking scientifically based harmonized
technical procedures for pharmaceutical
development. One of the goals of
harmonization is to identify and then
reduce differences in technical
requirements for drug development
among regulatory agencies.
ICH was organized to provide an
opportunity for tripartite harmonization
initiatives to be developed with input
from both regulatory and industry
representatives. FDA also seeks input
from consumer representatives and
others. ICH is concerned with
harmonization of technical
requirements for the registration of
pharmaceutical products among three
regions: The European Union, Japan,
and the United States. The six ICH
sponsors are the European Commission,
the European Federation of
Pharmaceutical Industries Associations,
the Japanese Ministry of Health, Labour,
and Welfare, the Japanese
Pharmaceutical Manufacturers
Association, the Centers for Drug
Evaluation and Research and Biologics
Evaluation and Research, FDA, and the
Pharmaceutical Research and
Manufacturers of America. The ICH
Secretariat, which coordinates the
preparation of documentation, is
provided by the International
Federation of Pharmaceutical
Manufacturers Associations (IFPMA).
The ICH Steering Committee includes
representatives from each of the ICH
sponsors and the IFPMA, as well as
observers from the World Health
Organization, Health Canada, and the
European Free Trade Area.
In June 2006, the ICH Steering
Committee agreed that a draft guidance
entitled ‘‘Q4B Regulatory Acceptance of
Analytical Procedures and/or
Acceptance Criteria; Annex 1: Residue
on Ignition/Sulfated Ash General
Chapter’’ should be made available for
public comment. The draft guidance is
the product of the Q4B Quality Expert
Working Group of the ICH. Comments
about this draft will be considered by
FDA and the Q4B Quality Expert
Working Group.
The draft guidance provides the
specific evaluation outcome from the
ICH Q4B process for the Residue on
Ignition/Sulphated Ash General Chapter
harmonization proposal originating
VerDate Aug<31>2005
20:06 Aug 07, 2006
Jkt 208001
from the three-party PDG. This draft
guidance is in the form of an annex to
the core ICH Q4B guidance. Once
finalized, the annex will provide
guidance to assist industry and
regulators in the implementation of the
specific topic evaluated by the ICH Q4B
process.
This draft guidance is being issued
consistent with FDA’s good guidance
practices regulation (21 CFR 10.115).
The draft guidance, when finalized, will
represent the agency’s current thinking
on this topic. It does not create or confer
any rights for or on any person and does
not operate to bind FDA or the public.
An alternative approach may be used if
such approach satisfies the
requirements of the applicable statutes
and regulations.
II. Comments
Interested persons may submit to the
Division of Dockets Management (see
ADDRESSES) written or electronic
comments on the draft guidance. Submit
a single copy of electronic comments or
two paper copies of any mailed
comments, except that individuals may
submit one paper copy. Comments are
to be identified with the docket number
found in brackets in the heading of this
document. The draft guidance and
received comments may be seen in the
Division of Dockets Management
between 9 a.m. and 4 p.m., Monday
through Friday.
III. Electronic Access
Persons with access to the Internet
may obtain the document at https://
www.fda.gov/ohrms/dockets/
default.htm, https://www.fda.gov/cder/
guidance/index.htm, or https://
www.fda.gov/cber/publications.htm.
Dated: July 31, 2006.
Jeffrey Shuren,
Assistant Commissioner for Policy.
[FR Doc. E6–12806 Filed 8–7–06; 8:45 am]
BILLING CODE 4160–01–S
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. 2006D–0297]
International Conference on
Harmonisation; Draft Guidance on Q4B
Regulatory Acceptance of Analytical
Procedures and/or Acceptance
Criteria; Availability
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
PO 00000
Notice.
Frm 00066
Fmt 4703
Sfmt 4703
45059
SUMMARY: The Food and Drug
Administration (FDA) is announcing the
availability of a draft guidance entitled
‘‘Q4B Regulatory Acceptance of
Analytical Procedures and/or
Acceptance Criteria.’’ The draft
guidance was prepared under the
auspices of the International Conference
on Harmonisation of Technical
Requirements for Registration of
Pharmaceuticals for Human Use (ICH).
The draft guidance describes a
procedure to facilitate acceptance by
regulatory authorities of
pharmacopoeial test methods (referred
to in the draft guidance as analytical
procedures and/or acceptance criteria
(APAC)) for use in the three ICH
regions. The draft guidance is intended
to facilitate regulatory acceptance of
these proposed test methods and their
interchangeability with test methods
contained in the local regional
pharmacopoeias, thus avoiding
redundant testing and different
acceptance criteria in favor of a common
testing strategy in each ICH regulatory
region. Elsewhere in this issue of
theFederal Register, FDA is announcing
the availability of a draft guidance
entitled ‘‘Q4B Regulatory Acceptance of
Analytical Procedures and/or
Acceptance Criteria; Annex 1: Residue
on Ignition/Sulphated Ash General.’’
DATES: Submit written or electronic
comments on the draft guidance by
October 10, 2006.
ADDRESSES: Submit written comments
on the draft guidance to the Division of
Dockets Management (HFA–305), Food
and Drug Administration, 5630 Fishers
Lane, rm. 1061, Rockville, MD 20852.
Submit electronic comments to https://
www.fda.gov/dockets/ecomments.
Submit written requests for single
copies of the draft guidance to the
Division of Drug Information (HFD–
240), Center for Drug Evaluation and
Research, Food and Drug
Administration, 5600 Fishers Lane,
Rockville, MD 20857; or the Office of
Communication, Training and
Manufacturers Assistance (HFM–40),
Center for Biologics Evaluation and
Research (CBER), Food and Drug
Administration, 1401 Rockville Pike,
Rockville, MD 20852–1448. The
guidance may also be obtained by mail
by calling CBER at 1–800–835–4709 or
301–827–1800. Send two self-addressed
adhesive labels to assist the office in
processing your requests. See the
SUPPLEMENTARY INFORMATION section for
electronic access to the draft guidance
document.
FOR FURTHER INFORMATION CONTACT:
Regarding the guidance: Robert H.
King, Sr., Center for Drug
E:\FR\FM\08AUN1.SGM
08AUN1
Agencies
[Federal Register Volume 71, Number 152 (Tuesday, August 8, 2006)]
[Notices]
[Pages 45058-45059]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E6-12806]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
[Docket No. 2006D-0296]
International Conference on Harmonisation; Draft Guidance on Q4B
Regulatory Acceptance of Analytical Procedures and/or Acceptance
Criteria; Annex on Residue on Ignition/Sulphated Ash General Chapter;
Availability
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The Food and Drug Administration (FDA) is announcing the
availability of a draft guidance entitled ``Q4B Regulatory Acceptance
of Analytical Procedures and/or Acceptance Criteria; Annex 1: Residue
on Ignition/Sulphated Ash General.'' The draft guidance was prepared
under the auspices of the International Conference on Harmonisation of
Technical Requirements for Registration of Pharmaceuticals for Human
Use (ICH). The draft guidance provides the outcome of the ICH Q4B
evaluation of the Residue on Ignition/Sulphated Ash General Chapter
harmonized text from each of the three pharmacopoeias (United States,
European, and Japanese) represented by the Pharmacopoeial Discussion
Group (PDG). The draft guidance conveys acceptance of the three
pharmacopoeial methods by the three ICH regulatory regions and provides
specific information regarding the acceptance. The draft guidance is
intended to recognize the interchangeability between the local regional
pharmacopoeias, thus avoiding redundant testing and different
acceptance criteria in favor of a common testing strategy in each
regulatory region. Elsewhere in this issue of the Federal Register, FDA
is announcing the availability of a draft guidance entitled ``Q4B
Regulatory Acceptance of Analytical Procedures and/or Acceptance
Criteria.''
DATES: Submit written or electronic comments on the draft guidance by
October 10, 2006.
ADDRESSES: Submit written requests for single copies of the draft
guidance to the Division of Drug Information (HFD-240), Center for Drug
Evaluation and Research, Food and Drug Administration, 5600 Fishers
Lane, Rockville, MD 20857; or the Office of Communication, Training and
Manufacturers Assistance (HFM-40), Center for Biologics Evaluation and
Research (CBER), Food and Drug Administration, 1401 Rockville Pike,
Rockville, MD 20852-1448. The guidance may also be obtained by mail by
calling CBER at 1-800-835-4709 or 301-827-1800. Send two self-addressed
adhesive labels to assist the office in processing your requests.
Submit written comments on the draft guidance to the Division of
Dockets Management (HFA-305), Food and Drug Administration, 5630
Fishers Lane, rm. 1061, Rockville, MD 20852. Submit electronic comments
to https://www.fda.gov/dockets/ecomments. See the SUPPLEMENTARY
INFORMATION section for electronic access to the draft guidance
document.
FOR FURTHER INFORMATION CONTACT:
Regarding the guidance: Robert H. King, Sr., Center for Drug
Evaluation and Research (HFD-003), Food and Drug Administration, 10993
New Hampshire Ave., Bldg. 21, rm. 3542, Silver Spring, MD 20993-0002,
301-796-1242; or
Christopher Joneckis, Center for Biologics Evaluation and Research
(HFM-20), Food and Drug Administration, 1401 Rockville Pike, Rockville,
MD 20852, 301-435-5681.
Regarding the ICH:Michelle Limoli, Office of International Programs
(HFG-1), Food and Drug Administration, 5600 Fishers Lane,Rockville, MD
20857, 301-827-4480.
SUPPLEMENTARY INFORMATION:
[[Page 45059]]
I. Background
In recent years, many important initiatives have been undertaken by
regulatory authorities and industry associations to promote
international harmonization of regulatory requirements. FDA has
participated in many meetings designed to enhance harmonization and is
committed to seeking scientifically based harmonized technical
procedures for pharmaceutical development. One of the goals of
harmonization is to identify and then reduce differences in technical
requirements for drug development among regulatory agencies.
ICH was organized to provide an opportunity for tripartite
harmonization initiatives to be developed with input from both
regulatory and industry representatives. FDA also seeks input from
consumer representatives and others. ICH is concerned with
harmonization of technical requirements for the registration of
pharmaceutical products among three regions: The European Union, Japan,
and the United States. The six ICH sponsors are the European
Commission, the European Federation of Pharmaceutical Industries
Associations, the Japanese Ministry of Health, Labour, and Welfare, the
Japanese Pharmaceutical Manufacturers Association, the Centers for Drug
Evaluation and Research and Biologics Evaluation and Research, FDA, and
the Pharmaceutical Research and Manufacturers of America. The ICH
Secretariat, which coordinates the preparation of documentation, is
provided by the International Federation of Pharmaceutical
Manufacturers Associations (IFPMA).
The ICH Steering Committee includes representatives from each of
the ICH sponsors and the IFPMA, as well as observers from the World
Health Organization, Health Canada, and the European Free Trade Area.
In June 2006, the ICH Steering Committee agreed that a draft
guidance entitled ``Q4B Regulatory Acceptance of Analytical Procedures
and/or Acceptance Criteria; Annex 1: Residue on Ignition/Sulfated Ash
General Chapter'' should be made available for public comment. The
draft guidance is the product of the Q4B Quality Expert Working Group
of the ICH. Comments about this draft will be considered by FDA and the
Q4B Quality Expert Working Group.
The draft guidance provides the specific evaluation outcome from
the ICH Q4B process for the Residue on Ignition/Sulphated Ash General
Chapter harmonization proposal originating from the three-party PDG.
This draft guidance is in the form of an annex to the core ICH Q4B
guidance. Once finalized, the annex will provide guidance to assist
industry and regulators in the implementation of the specific topic
evaluated by the ICH Q4B process.
This draft guidance is being issued consistent with FDA's good
guidance practices regulation (21 CFR 10.115). The draft guidance, when
finalized, will represent the agency's current thinking on this topic.
It does not create or confer any rights for or on any person and does
not operate to bind FDA or the public. An alternative approach may be
used if such approach satisfies the requirements of the applicable
statutes and regulations.
II. Comments
Interested persons may submit to the Division of Dockets Management
(see ADDRESSES) written or electronic comments on the draft guidance.
Submit a single copy of electronic comments or two paper copies of any
mailed comments, except that individuals may submit one paper copy.
Comments are to be identified with the docket number found in brackets
in the heading of this document. The draft guidance and received
comments may be seen in the Division of Dockets Management between 9
a.m. and 4 p.m., Monday through Friday.
III. Electronic Access
Persons with access to the Internet may obtain the document at
https://www.fda.gov/ohrms/dockets/default.htm, https://www.fda.gov/cder/
guidance/index.htm, or https://www.fda.gov/cber/publications.htm.
Dated: July 31, 2006.
Jeffrey Shuren,
Assistant Commissioner for Policy.
[FR Doc. E6-12806 Filed 8-7-06; 8:45 am]
BILLING CODE 4160-01-S